Investor Relations (IR) Questions: Apricus Biosciences $APRI
Click here to return to the biotech IRQ Index
Answers received: January 2013
1) When is the last time APRI raised cash through an offering (diluted)?
a. The most recent financing took place in February 2012.
2) How much cash (not cash equivalents) does APRI have?
a. Apricus’ disclosures don’t separate cash from cash equivalents. Combined, the company had $16.8 million as of September 30, 2012.
3) What and approximately when is the next known catalyst?
a. The Company announced their 2013 goals in a press release dated Jan 3, 2013, which can be found herehttp://apricusbio.com/press_01032013.html. Anticipated milestones include:
i. Commercial launch of Vitaros in Canada through Abbott Laboratories expected in the first half of 2013.
ii. European approval of Vitaros via the Decentralized Procedure with Netherlands as the Reference Member State expected to occur in first half of 2013.
iii. Feedback from regulatory agencies regarding next clinical steps for Femprox expected in 2013.
4) What is APRI's quarterly cash burn?
a. The Company has made no formal disclosures about quarterly cash burn, but quarterly financial statements (Form 10-Q’s) have been filed with the SEC and are in the public domain. These filings contain detailed financial statements and can be found here http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=apri&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
5) Does APRI have an existing line of credit and if so how much can they draw against it?
a. No, there are no credit arrangements currently in place. For more detail about this item please refer to page 19 of the Company’s 1Q 2012 Form 10-Q (filed May 10, 2012).
1) When is the last time APRI raised cash through an offering (diluted)?
a. The most recent financing took place in February 2012.
2) How much cash (not cash equivalents) does APRI have?
a. Apricus’ disclosures don’t separate cash from cash equivalents. Combined, the company had $16.8 million as of September 30, 2012.
3) What and approximately when is the next known catalyst?
a. The Company announced their 2013 goals in a press release dated Jan 3, 2013, which can be found herehttp://apricusbio.com/press_01032013.html. Anticipated milestones include:
i. Commercial launch of Vitaros in Canada through Abbott Laboratories expected in the first half of 2013.
ii. European approval of Vitaros via the Decentralized Procedure with Netherlands as the Reference Member State expected to occur in first half of 2013.
iii. Feedback from regulatory agencies regarding next clinical steps for Femprox expected in 2013.
4) What is APRI's quarterly cash burn?
a. The Company has made no formal disclosures about quarterly cash burn, but quarterly financial statements (Form 10-Q’s) have been filed with the SEC and are in the public domain. These filings contain detailed financial statements and can be found here http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=apri&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
5) Does APRI have an existing line of credit and if so how much can they draw against it?
a. No, there are no credit arrangements currently in place. For more detail about this item please refer to page 19 of the Company’s 1Q 2012 Form 10-Q (filed May 10, 2012).